Please use this identifier to cite or link to this item:
Title: The effectiveness of platelet-rich plasma injections in gluteal tendinopathy - a randomised, double-blind controlled trial comparing a single platelet-rich plasma injection with a single corticosteroid injection.
Epworth Authors: Fitzpatrick, Jane
O'Donnell, John
Other Authors: Bulsara, Max
Zheng, Ming
McCrory, Paul Robert
Keywords: Platelet-Rich Plasma Injection
Gluteal Tendinopathy
Corticosteroid Injection
Treatment Outcome
Lateral Hip Pain
Trochanteric Pain Syndrome
Gluteus Medius/Minimus Tendinopathy
Modified Harris Hip Score
Patient Acceptable Symptomatic State
Minimally Important Clinical Difference
Chronic Gluteal Tendinopathy
Clinical Improvement
Clinical Recovery
Sports Medicine
Clinical Effectiveness
Musculoskeletal Clinical Institute, Epworth HealthCare, Victoria, Australia
Issue Date: Jun-2017
Citation: Epworth Research Institute Research Week 2017; Poster 11: pp 34
Conference Name: Epworth Research Institute Research Week 2017
Conference Location: Epworth Research Institute, Victoria, Australia
Abstract: IMPORTANCE: Gluteus medius/minimus tendinopathy is a common cause of lateral hip pain or greater trochanteric pain syndrome. OBJECTIVE: There would be no difference in the modified Harris Hip score between a single Platelet-Rich-Plasma (PRP) injection compared to a corticosteroid injection (CSI) in the treatment of gluteal tendinopathy. DESIGN: Randomised Controlled Clinical Trial; Level of evidence 1, recruitment 29 May 2013 to May 2015, follow-up September 2016. Treating/assessing clinicians and subjects were blinded to treatment. PARTICIPANTS: 228 consecutive patients referred with gluteal tendinopathy were screened to enrol 80 participants. 148 excluded (refusal 48, previous surgery 39, sciatica 28, osteoarthritis 17, full thickness tears tendons 17, other 22). INTERVENTION: Subjects were randomised (1:1) to receive either a blinded glucocorticoid or platelet-rich plasma injection intra-tendinously under ultrasound guidance. MAIN OUTCOME MEASURE: A pain and functional assessment was performed using a Modified Harris Hip Score (MHHS) questionnaire at 0, 2, 6 and 12 weeks and patient acceptable symptomatic state (PASS) and minimally important clinical difference (MICD) at 12 weeks. RESULTS: Subjects had a mean age of 60, a ratio of female to male of 9:1 and mean length of symptoms >14 months. Pain and function measured by the mean MHHS showed no difference at 2 weeks CSI 66.95 (SD 15.14) vs PRP 65.23 (SD 11.60) or 6 week CSI 69.51 (SD 14.78) vs PRP 68.79 (SD 13.33). The mean MHHS was significantly improved at 12 weeks PRP 74.05 (SD 13.92) compared to the CSI group with a mean score of 67.13 (SD 16.04, p = 0.048). The PRP group achieved a PASS score of 74 at 12 weeks, reflecting clinical recovery. The proportion of subjects who achieved the MICD of more than 8 points at 12 weeks was 21/37 (56.7%) in the CSI group and 32/39 (82%) in the PRP group (p = 0.016). CONCLUSION: Patients with chronic gluteal tendinopathy >4 months, diagnosed with both clinical and radiological examinations, achieved greater clinical improvement at 12 weeks when treated with a single PRP injection than those treated with a single corticosteroid injection.
Type: Conference Poster
Affiliated Organisations: University of Western Australia, Perth, Australia
University of Notre Dame, Perth, Australia
University of Melbourne, Parkville, Melbourne, Australia
Type of Clinical Study or Trial: Randomized Controlled Clinical Trial
Appears in Collections:Musculoskeletal
Research Month

Files in This Item:
There are no files associated with this item.

Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.